Product Information
METFORMIN HCL 850 MG TABLET is a generic product labeled by Legacy Pharmaceutical Packaging, LLC, priced at $0.0240 per EA under NDC 68645058359. Its NADAC has been published 337 times since Oct 9, 2019.
FDA first approved this application on Apr 22, 2010. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
850 mg/1
Manufacturer
Legacy Pharmaceutical Packaging, LLCNDC
68645058359
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
METFORMIN HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA090564FDA Approved
4/22/2010
TE Code
AB
On Market Since
6/7/2019
Pharmacological Classes
Price Statistics
The NADAC for METFORMIN HCL 850 MG TABLET has been published 337 times since Oct 9, 2019, and over the history we have for it it has declined 18.9%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.0240 per EA |
|---|---|
| All-time high | $0.0312 (Nov 13, 2019) |
| All-time low | $0.0196 (May 22, 2024) |
| 52-week high | $0.0248 |
| 52-week low | $0.0224 |
| Median price | $0.0266 |
| Average price | $0.0262 |
| Largest weekly change | +26.0% (Jun 19, 2024) |
| Weeks tracked | 337 |
| Tracking since | Oct 9, 2019 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Metformin hydrochloride market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Legacy Pharmaceutical Packaging, LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Metformin hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Biguanide class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of METFORMIN HCL 850 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for METFORMIN HCL 850 MG TABLET, manufactured by Legacy Pharmaceutical Packaging, LLC, is $0.0240 per EA (NDC 68645058359), effective Sep 30, 2026.
How has the price of METFORMIN HCL 850 MG TABLET changed over time?
Over the history we have for it, the NADAC for METFORMIN HCL 850 MG TABLET has declined 18.9%. It has been tracked across 337 weekly CMS publications since Oct 9, 2019.
What are the highest and lowest recorded NADAC prices for METFORMIN HCL 850 MG TABLET?
Since Oct 9, 2019, the NADAC for METFORMIN HCL 850 MG TABLET has ranged from a low of $0.0196 (May 22, 2024) to a high of $0.0312 (Nov 13, 2019), with a median of $0.0266 per EA.
Are there cheaper alternatives to METFORMIN HCL 850 MG TABLET?
No other NADAC-published product currently shares the active ingredient and strength of METFORMIN HCL 850 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures METFORMIN HCL 850 MG TABLET?
METFORMIN HCL 850 MG TABLET (NDC 68645058359) is labeled by Legacy Pharmaceutical Packaging, LLC, and CMS classifies it as a generic product.